An Open Label Multi-Centre Preoperative Window of Opportunity Study of Afatinib in Stage Ia to IIb Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Acronyms ABLE
- 01 Jul 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 31 Aug 2018 Biomarkers information updated
- 17 Sep 2015 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.